LIU Bing,YANG Hongtao,PENG Yiwen,et al.Effect of acupuncture and moxibustion in the treatment of IgA nephropathy based on mucosal immunity[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(02):128-131.
LIU Bing,YANG Hongtao,PENG Yiwen,et al.Effect of acupuncture and moxibustion in the treatment of IgA nephropathy based on mucosal immunity[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(02):128-131. DOI: 10.16025/j.1674-1307.2025.02.003.
Effect of acupuncture and moxibustion in the treatment of IgA nephropathy based on mucosal immunity
MCGROGAN A , FRANSSEN CFM , DE VRIES CS . The incidence of primary glomerulonephritis worldwide: a systematic review of the literature [J ] . Nephrol Dial Transplant , 2011 , 26 ( 2 ): 414 - 430 .
STAMELLOU E , SEIKRIT C , TANG SCW , et al . IgA nephropathy [J ] . Nat Rev Dis Primers , 2023 , 9 ( 1 ): 67 .
ZAIDI O , DU F , TANG Z , et al . Review on epidemiology,disease burden, and treatment patterns of IgA nephropathy in select APAC countries [J ] . BMC nephrology , 2024 , 25 ( 1 ): 136 .
BARRATT J , LAFAYETTE RA , ZHANG H , et al . IgA nephropathy:the lectin pathway and implications for targeted therapy [J ] . Kidney Int , 2023 , 104 ( 2 ): 254 - 264 .
MYETTE JR , KANO T , SUZUKI H , et al . A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy [J ] . Kidney International , 2019 , 96 ( 1 ): 104 - 116 .
ROVIN BH , BARRATT J , HEERSPINK HJL , et al . Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial [J ] . Lancet , 2023 , 402 ( 10417 ): 2077 - 2090 .
HE JW , ZHOU XJ , LYU JC , et al . Perspectives on how mucosal immune responses,infections and gut microbiome shape IgA nephropathy and future therapies [J ] . Theranostics , 2020 , 10 ( 25 ): 11462 - 11478 .
SUZUKI H , KIRYLUK K , NOVAK J , et al . The pathophysiology of IgA nephropathy [J ] . J Am Soc Nephrol , 2011 , 22 ( 10 ): 1795 - 1803 .
SELVASKANDAN H , BARRATT J , CHEUNG CK . Immunological drivers of IgA nephropathy: exploring the mucosa-kidney link [J ] . Int J Immunogenet , 2022 , 49 ( 1 ): 8 - 21 .
COPPO R . The intestine-renal connection in IgA nephropathy [J ] . Nephrol Dial Transplant , 2015 , 30 ( 3 ): 360 - 366 .
BARRATT J , KRISTENSEN J , PEDERSEN C , et al . Insights on nefecon®, a targeted-release formulation of budesonide and its selective immunomodulatory effects in patients with IgA nephropathy [J ] . Drug Des Devel Ther , 2024 , 18 : 3415 - 3428 .
LAFAYETTE R , KRISTENSEN J , STONE A , et al . Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd):2-year results from a randomised phase 3 trial [J ] . Lancet , 2023 , 402 ( 10405 ): 859 - 870 .
ULLOA L , QUIROZ-GONZALEZ S , TORRES-ROSAS R . Nerve stimulation: immunomodulation and control of inflammation [J ] . Trends Mol Med , 2017 , 23 ( 12 ): 1103 - 1120 .
PABST O , IZCUE A . Secretory IgA: controlling the gut microbiota [J ] . Nat Rev Gastroenterol Hepatol , 2022 , 19 ( 3 ): 149 - 150 .
ZHANG X , TAN R , LAM WC , et al . PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration [J ] . Syst Rev , 2020 , 9 ( 1 ): 247 .
ROLLENSKE T , BURKHALTER S , MUERNER L , et al . Parallelism of intestinal secretory IgA shapes functional microbial fitness [J ] . Nature , 2021 , 598 ( 7882 ): 657 - 661 .
KAU AL , PLANER JD , LIU J , et al . Functional characterization of IgA-targeted bacterial taxa from undernourished Malawian children that produce diet-dependent enteropathy [J ] . Sci Transl Med , 2015 , 7 ( 276 ): 276ra24 .
ZHU MF , XING X , LEI S , et al . Electroacupuncture at bilateral zusanli points(st36)protects intestinal mucosal immune barrier in sepsis [J ] . Evid Based Complement Alternat Med , 2015 : 639412 .